Skip to content

Use Of Homoeopathy In Complaints Of Menopause

Role Of Individualized Homoeopathic Medicine In Post Menopausal Genitourinary Syndrome By Using Synthesis Repertory: An Open Label Prospective Clinical Study - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080955
Enrollment
40
Registered
2025-02-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N951- Menopausal and female climactericstates

Interventions

Intervention1: Individualized Homoeopathic Medicine: Individualized homoeopathic medicine will be prescribed after the proper case taking and repertorisation of the case using rubrics within synthesis

Sponsors

National Institute Of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female patients between 40-60 years of age having natural menopause with 12 months of amenorrhea, clinically diagnosed with Genitourinary Syndrome of Menopause using the Vulvovaginal Symptom Questionnaire (VSQ). 2. Female patients of all socio-economic status and all religions. 3. Willingness to actively participate in the study, attend regular follow-up assessments, and adhere to the prescribed homeopathic treatment plan. 4. Patients who can read/understand Hindi, English, or Bengali. 5. Female patients with known but controlled systemic diseases. 6. Stable overall health without acute or severe medical conditions.

Exclusion criteria

Exclusion criteria: 1. Female Patients who have undergone Hysterectomy. 2. Female patients who are having malignant diseases 3. Female patients using any medicine or hormone therapy containing oestrogen and progesterone since 3months. 4. Female patients suffering from any life threatening/ psychiatric illness or immune compromised state. 5. Female patients who are on substance abuse or dependence. 6. Dermatological conditions of vulva such as lichen sclerosus or planus, eczema, dermatitis; Vulvodynia; Vaginosis; Chronic vulvovaginitis. 7. Inability or unwillingness to comply with scheduled follow-up visits and assessments

Design outcomes

Primary

MeasureTime frame
Vulvovaginal Symptom Questionnaire (VSQ21)Timepoint: Baseline & 6 months

Secondary

MeasureTime frame
Socio-demographic dataTimepoint: After 6 months

Countries

India

Contacts

Public ContactDr Birendra Prasad Srivastava

National Institute Of Homoeopathy

dr.srivastava61@gmail.com7003178867

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026